Drug Profile
Affitope AD03
Alternative Names: AD 03; Affitope-AD03; Alzheimer AD03; MimoVaxLatest Information Update: 02 Jul 2023
Price :
$50
*
At a glance
- Originator AFFiRiS
- Class Alzheimer vaccines
- Mechanism of Action Amyloid beta-protein inhibitors; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 05 May 2016 Discontinued - Phase-I for Alzheimer's disease in Austria (SC)
- 31 Dec 2011 AFFiRiS initiates enrolment (by invitation only) in a phase Ib follow-up trial in Alzheimer's disease in Austria (NCT01568086)
- 01 Nov 2011 AFFiRiS completes a phase I trial in Alzheimer's disease in Austria (NCT01309763)